Seeking Alpha
View as an RSS Feed

Timeless Wealth  

View Timeless Wealth's Comments BY TICKER:

Latest  |  Highest rated
  • Prolor Biotech: A Critical Year For Company With Results Expected For Lead Drug In Development [View article]
    Per the CEO's comments on their Q3 conference call, Teva is in fact looking to "expand and invest in other companies right now". See SA's transcript section.
    Dec 6, 2012. 02:40 PM | Likes Like |Link to Comment
  • Trovagene Poised To Lead The Next Generation Of Molecular Diagnostics Technology [View article]
    Can you provide a link(s) to substantiate any of this?
    Jul 1, 2012. 07:09 PM | Likes Like |Link to Comment
  • Repros Therapeutics: More Holes Than A Block Of Swiss Cheese [View article]
    "no physician in their right mind would prescribe generic clomifene due to litigation risk"

    Jun 14, 2012. 08:33 PM | Likes Like |Link to Comment
  • Oculus: Financial Distress, Concentration Risk, And Other Red Flags [View article]
    UPDATE: Oculus priced an offering of 3.5 Million shares at a weighted average of $0.90 this morning, discounted >23% from last week's close. Investors got the short end of the stick with 100% warrant coverage on top.
    Apr 23, 2012. 02:35 PM | Likes Like |Link to Comment
  • NovaBay Anti-Infective Programs Mitigate Risk [View article]
    Len, this is very well written. NovaBay has a very unique product offering in a segment that most investors do not yet understand. Analysts' discounted cash flow models suggest a valuation north of $2/share on the conservative end. There's also validation on the end of a partnership with Galderma - a global leader in dermatology who has effectively committed over $62 million to develop NovaBay's Aganocide for the treatment of Impetigo (see

    Whichever way you look at this company, it seems grossly undervalued.
    Apr 3, 2012. 08:17 PM | Likes Like |Link to Comment
  • Oculus: Financial Distress, Concentration Risk, And Other Red Flags [View article]
    Oculus's dividend history isn't an "argument", it's fact. For many investors dividends make up a sizeable portion of total return. Inevitably, the only thing Oculus's investors have realized to-date are [large] capital losses. In FY2012 Oculus will only add to a growing $130MM+ deficit. Solvency has perpetually plagued the company; growth is pegged to a single distributor; and there is a massive amount of dilutive overhang.

    When exactly are they "on the way to turn into net-positive earnings" given that expenses have largely offset growth in sales - not to mention that the growth was partially due to a one-time gain in royalty?

    You (and investors, in general) should find it troubling that management felt the need to regurgitate month-old news in a release this morning.
    Mar 23, 2012. 09:49 AM | Likes Like |Link to Comment
  • Oculus: Financial Distress, Concentration Risk, And Other Red Flags [View article]
    "[...]I took advantage of figuring out that nothing has changed at OCLS". -- Precisely why it should concern investors.

    The folly in investing before researching a company is that information has a tendency of surfacing at the worst possible time. And yet the facts summarized in our report have been available to the public for quite some time. We highlighted material risks that have not been factored into the price (yet). Of course we only grazed the surface, and there are other risks (not highlighted in this report) that make this company unattractive on a risk/reward basis.
    Mar 22, 2012. 04:43 PM | Likes Like |Link to Comment
  • Vivus: Another Potentially Safe Short Play On Likely Drug Rejection [View article]
    Qnexa, not Qnesa, will be viewed by the FDA on a balance of benefits to risk(s). The risks, briefly described in this article, are minor when weighed with the potency of Qnexa as a weight-loss drug. The FDA is 'safety-biased' if you will, but they also understand obesity leads to often fatal diseases and inevitably a poorer quality of life. The FDA is also well aware of the growing costs of a redundant healthcare system and the need for drastic change. It’s very speculative to dismiss the approval or suggest a CV study will be asked of Vivus before product approval.
    Feb 27, 2012. 08:16 PM | 3 Likes Like |Link to Comment
  • How Qnexa's Positive Panel Review Generated Alpha For Short Sellers [View article]

    The tendency for shares of Vivus to rise as an FDA decision looms is exaggerated by the large unmet need for an efficacious, prescription weight-loss medication. Post-approval it becomes a lot clearer - particularly once the momentum crowd fades - if the company is worth $30 per share, more, or less. Dendreon saw the same thing when its immunotherapy drug for prostate cancer was approved by the FDA. Shares soared on optimism, which, as it turns out, was premature - the product took longer than expected to reach end-users because of a run-in with reimbursement and the learning curve that comes with launching your first commercial product.
    Feb 24, 2012. 04:11 PM | Likes Like |Link to Comment
  • How Qnexa's Positive Panel Review Generated Alpha For Short Sellers [View article]
    The intent was to demonstrate that Arena and Orexigen are derivative of a speculative case, in itself. Therefore their large shifts in price were fundamentally flawed.
    Feb 24, 2012. 01:00 PM | Likes Like |Link to Comment
  • How Qnexa's Positive Panel Review Generated Alpha For Short Sellers [View article]
    You've missed the point: after Wednesday's news, shares of these equities were overbought. Short-sellers created alpha by taking advantage of temporarily mispriced market(s). Naturally, all three stocks corrected in the ensuing trading session. Arena forfeited all of its earlier gains (suggesting weakness and lack of confidence on the part of its investors) and Orexigen has further downside.
    Feb 24, 2012. 11:26 AM | Likes Like |Link to Comment
  • How Much Is Jeremy Lin Worth To MSG? [View article]

    Excellent piece.
    Feb 14, 2012. 05:05 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: Anti-Inflammatory Medicine Awaits FDA Guidance On Pivotal Juncture [View article]
    An initial osteoarthritis-in-the-... trial in Australia enrolled and tested Ampion in a three-arm, 60 patient study. Ampio then launched a study for Ampion as a stand-alone therapy versus placebo in a randomized, double-blinded study at Centers for Allergy and Asthma in Denver, Colorado for nasal inflammation, which enrolled an additional 20 patients. Positive data from the initial osteoarthritis-in-the-... trial gave Ampio the validation and safety data needed to test Ampio as a stand-alone therapeutic in the 40-patient follow-on trial we're now discussing.

    In aggregate, at least 120 patients received Ampion in clinical trials. No adverse events related to treatment with Ampion were reported. Ampion's innate composition, a naturally occurring human molecule, itself, suggests it is well-tolerated as a therapy.
    Feb 1, 2012. 03:45 PM | Likes Like |Link to Comment
  • Emerging Technologies In Brain Cancer Therapy [View article]
    Last week ImmunoCellular traded for less than $1 per share. And two years ago, shares went for half of today's price. Prices continually change in the marketplace. A form S-1 was filed in November, so investors were well aware that the company would be raising capital and could dilute shareholder value. But more importantly, when investors invest in the company, they're not just buying an interest in its shares, they're also helping fund a therapy that betters the lives of brain cancer patients. This year, among other things, ImmunoCellular Therapeutics will report interim data from a highly-anticipated Phase II study of ICT-107 in patients with glioblastoma. Strong data would signal a very significant pivot in value for the company and its shareholders.
    Jan 21, 2012. 04:04 PM | Likes Like |Link to Comment
  • Ampio Pharmaceuticals: Anywhere But Straight Out Of Isolagen's Playbook [View article]
    That piece was an analysis of sentiment from someone observing from the sidelines. It was geared towards a potential trading opportunity. Of course, Ian, anyone can seem brilliant after the fact.

    The mention was in response to what we felt was an apples to oranges comparison made earlier.
    Jan 13, 2012. 02:26 PM | Likes Like |Link to Comment